ArticleKidney international reports2025
A Systematic Review of Treatment for Acute Interstitial Nephritis.
Article in Kidney international reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Acute interstitial nephritis (AIN) is a common cause of acute kidney injury. It is characterized by tubular inflammation with eosinophils histologically. The mainstay treatment for AIN includes early diagnosis; underlying infection or systemic disease treatment; cessation of the offending agent; and corticosteroid therapy, when indicated. This systematic review aims to evaluate the efficacy and safety of pharmacotherapy treatments for AIN by assessing treatment outcomes and adverse effects. Methods: PubMed, Embase, Cochrane Library, and other major databases were systematically searched in June 2024 after registration with the International Prospective Register of Systematic Reviews. Manual searches of the references in relevant articles were conducted. Studies focusing on the treatment of AIN cases that were diagnosed histologically were included. A fixed-effects meta-analysis and meta-regression were performed using Stata SE 16. Results: A total of 3597 articles were eligible for screening. Twenty-three articles were included in the systematic review. There were 3 randomized controlled trials, 4 case series, and 16 retrospective cohort studies. Corticosteroids were the primary treatment in most of the studies, with 1 study evaluating the use of mycophenolate mofetil (MMF) in steroid-refractory patients. A meta-analysis of 3 studies showed that prednisolone use improved renal outcomes. There was significant variability across studies in dosing, treatment duration, and timing of initiation. Adverse events associated with corticosteroids were likely underreported. Conclusion: Consistent evidence supporting the use of corticosteroids for treating AIN needs to be more comprehensive. There needs to be a clear consensus on the optimal treatment regimen. High-quality randomized controlled trials are required to help establish evidence-based guidelines for treating AIN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.